Document:

EX-4.1

 EXHIBIT 4.1 

CITIBANK CREDIT CARD ISSUANCE TRUST 

Citiseries 
 Class
2017-A8 Notes 
 Issuer Certificate 

Pursuant to Sections 202 and 301(h) of the Indenture 

Reference is made to the Second Amended and Restated Indenture dated as of September 26, 2000, as amended and restated as of
August 9, 2011, and as further amended and restated as of November 10, 2016, between Citibank Credit Card Issuance Trust (the “Issuer”) and Deutsche Bank Trust Company Americas, as trustee (as so further amended and restated, the
“Indenture”). Capitalized terms used herein that are not otherwise defined have the meanings set forth in the Indenture. All references herein to designated Sections are to the designated Sections of the Indenture. 

Section 301(h) provides that the Issuer may from time to time create a tranche of Notes either by or pursuant to an Issuer Certificate
setting forth the principal terms thereof. Pursuant to this Issuer Certificate, there is hereby created a tranche of Notes having the following terms: 

Series Designation: Citiseries. This series is included in Group 1. 

Tranche Designation: $1,100,000,000 1.86% Class 2017-A8 Notes of August 2020 (Legal Maturity Date August 2022) (hereinafter, the “Class 2017-A8
Notes”) 
 Currency: The Class 2017-A8 Notes will be payable, and denominated, in Dollars. 

Denominations: The Class 2017-A8 Notes will be issuable in minimum denominations of $100,000 and multiples of $1,000 in excess of that amount. 

Issuance Date: August 8, 2017 
 Initial Principal
Amount: $1,100,000,000 
 Issue Price: 99.98842% 

Interest Rate: 1.86% per annum, calculated on the basis of a 360 day year of twelve 30 day months. 

Scheduled Interest Payment Dates: The 7th day of each February and August, beginning February 2018. 

Each payment of interest on the Class 2017-A8 Notes will include all interest accrued from and including the preceding Interest Payment Date — or, for
the first interest period, from and including the Issuance Date — to and including the day preceding the current Interest Payment Date, plus any interest accrued but not previously paid. 

  

 The first deposit targeted to be made to the Interest Funding sub-Account for the Class 2017-A8 Notes will be on
the September 7, 2017 Interest Deposit Date and in an amount equal to $1,648,166.67. 
 Expected Principal Payment Date: August 7, 2020

 Legal Maturity Date: August 8, 2022 

Monthly Principal Date: For the month in which the Expected Principal Payment Date occurs, August 7, 2020, and for each other month, the 7th day
of such month, or if such day is not a Business Day, the next following Business Day. 
 Required Subordinated Amount of Class B Notes:
$65,812,010.00 
 Required Subordinated Amount of Class C Notes: $87,749,310.00 

Controlled Accumulation Amount: $91,666,666.67 
 Form
of Notes: The Class 2017-A8 Notes will be issued as Global Notes. The Global Notes will initially be registered in the name of Cede & Co., as nominee of The Depository Trust Company, and will be exchangeable for individual Notes only in
accordance with the provisions of Section 204(c). 
 Additional Issuances of Class 2017-A8 Notes: The Issuer may at any time and from time to
time issue additional Class 2017-A8 Notes, subject to the satisfaction of (i) the conditions precedent set forth in Section 311(a) and (ii) the following conditions: 

 

	 	(a)	The Issuer has obtained written confirmation from each Rating Agency that there will be no Ratings Effect with respect to the then outstanding Class 2017-A8 Notes as a result of the issuance of such additional Class
2017-A8 Notes; 

  

	 	(b)	As of the date of issuance of the additional Class 2017-A8 Notes, all amounts due and owing to the Holders of the then outstanding Class 2017-A8 Notes have been paid and there is no Nominal Liquidation Amount Deficit
with respect to the then outstanding Class 2017-A8 Notes; 

  

	 	(c)	The additional Class 2017-A8 Notes will be fungible with the original Class 2017-A8 Notes for federal income tax purposes; 

  

	 	(d)	If Holders of the then outstanding Class 2017-A8 Notes have the benefit of a Derivative Agreement, the Issuer will have obtained a Derivative Agreement for the benefit of the Holders of the additional Class 2017-A8
Notes; and 

  
 2 

	 	(e)	The ratio of the Controlled Accumulation Amount to the Initial Dollar Principal Amount of the Class 2017-A8 Notes, including the additional Class 2017-A8 Notes, will be equal to the ratio of the Controlled Accumulation
Amount (before giving effect to the additional issuance) to the Initial Dollar Principal Amount of the Class 2017-A8 Notes, excluding the additional Class 2017-A8 Notes. 

As of the date of issuance of additional Class 2017-A8 Notes, the Outstanding Dollar Principal Amount and Nominal Liquidation Amount of the Class 2017-A8
Notes will be increased to reflect the Initial Dollar Principal Amount of the additional Class 2017-A8 Notes. 
 Any outstanding Class 2017-A8 Notes and any
additional Class 2017-A8 Notes will be equally and ratably entitled to the benefits of the Indenture without preference, priority or distinction. 

Optional Redemption Provisions other than Section 1202 “Clean-Up Call”: None 

Additional Early Redemption Events or changes to Early Redemption Events: None 

Additional Events of Default or changes to Events of Default: None 

Business Day: means any day other than (a) a Saturday or Sunday or (b) any other day on which national banking associations or state banking
institutions in New York, New York or South Dakota, or any other state in which the principal executive offices of any Additional Seller are located, are authorized or obligated by law, executive order or governmental decree to be closed. 

Securities Exchange Listing: None 

  
 3 

 The Class 2017-A8 Notes shall have such other terms as are set forth in the form of Note attached
hereto as Exhibit A. Pursuant to Section 202, the form of Note attached hereto has been approved by the Issuer. 
  

			
	CITIBANK CREDIT CARD ISSUANCE TRUST
		
	By	 	     Citibank, N.A.,

    as Managing Beneficiary

		
		 	  

		 	[Name]
		 	[Title]

 Dated: August 8, 2017 

  
 4 

 Citiseries 

Class 2017-A8 Notes 

Reference is made to the resolutions adopted by the Board of Directors of Citibank, N.A. on January 25, 2017. The resolutions authorize
Citibank, N.A. from time to time to issue and sell, or to arrange for or participate in the issuance and sale of, one or more series and/or classes of pass-through certificates, participation certificates, commercial paper, notes, bonds or other
securities representing ownership interests in, or backed or secured by, pools of credit card receivables or interests therein (the “Receivables”) in an aggregate principal amount such that up to $45,000,000,000 of such certificates,
commercial paper, notes, bonds or other securities are outstanding at any one time and to sell, transfer, convey, assign or pledge or grant a security interest in all or any portion of its Receivables to Citibank Credit Card Master Trust I, Citibank
Omni Trust or any direct or indirect subsidiaries of Citibank, N.A., affiliates of Citigroup Inc., additional trusts or other entities or trustees in connection therewith on such terms as to be determined by the Citibank, N.A. Securitization Pricing
and Loan Committee (the “Pricing and Loan Committee”). 
 The undersigned, a duly authorized member of the Pricing and Loan
Committee, on behalf of such Pricing and Loan Committee, does hereby certify that the preceding Issuer Certificate, the terms of the tranche of Notes set forth in and to be created by the Issuer Certificate and the increase in the Invested Amount of
the Collateral Certificate resulting from the issuance of such Notes have been approved by such Pricing and Loan Committee. In addition, the following underwriting/selling agent terms with respect to this tranche of Notes have been approved by the
Pricing and Loan Committee: 
 Issue Price: 99.98842% 

Underwriting Commission: 0.25000% 

Proceeds to Issuer: 99.73842% 

Representative of the Underwriters: Citigroup Global Markets Inc. 

The preceding Issuer Certificate and this certification of Pricing and Loan Committee approval shall be, continuously from the time of their
execution, official records of Citibank, N.A. 
  

	
	[Name]
	Member of the Securitization Pricing and Loan Committee
	Citibank, N.A.

 Dated: August 8, 2017 

  
 5 

 Exhibit A 

FORM OF 
 CITISERIES 

1.86% CLASS 2017-A8 NOTES OF AUGUST 2020 

(Legal Maturity Date April 2022) 
  

			
	$[    ],000,000	  	REGISTERED
	CUSIP No. 17305E GG4	  	No. R-[1][2][3]

 UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK
CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 THE PRINCIPAL OF THIS NOTE IS PAYABLE AS SET FORTH HEREIN AND IN THE
INDENTURE REFERRED TO BELOW. ACCORDINGLY, THE OUTSTANDING PRINCIPAL AMOUNT OF THIS NOTE AT ANY TIME MAY BE LESS THAN THE AMOUNT SHOWN ON THE FACE HEREOF. 

CITIBANK CREDIT CARD ISSUANCE TRUST 

CITISERIES 
 1.86% CLASS 2017-A8
NOTES OF AUGUST 2020 
 (Legal Maturity Date August 2022) 

CITIBANK CREDIT CARD ISSUANCE TRUST, a trust formed and existing under the laws of the State of Delaware (including any successor, the “Issuer”),
for value received, hereby promises to pay to CEDE & CO., or its registered assigns, the principal amount of [            ] HUNDRED MILLION DOLLARS
($[            ],000,000). The Expected Principal Payment Date for this Note is August 7, 2020. The Legal Maturity Date for this Note is August 8, 2022. 

The Issuer hereby promises to pay interest on this Note on the 7th day of each February and August, beginning February 2018, until the principal of this Note
is paid or made available for payment, subject to certain limitations set forth in the Indenture. Interest will accrue on the 

  

 
outstanding principal amount of this Note for each interest period in an amount equal to the product of (i) the number of days in the interest period computed on the basis of a 360-day year
of twelve 30-day months, (ii) a rate per annum equal to the Class 2017-A8 Note Rate for such interest period, and (iii) the outstanding principal amount of this Note as of the preceding Interest Payment Date (after giving effect to any
payments of principal made on the preceding Interest Payment Date) or, with respect to the first Interest Payment Date, the initial principal amount of this Note. The Class 2017-A8 Note Rate will be determined as provided in the Indenture. 

If any Interest Payment Date or Principal Payment Date of this Note falls on a day that is not a Business Day, the required payment of interest or principal
will be made on the following Business Day. 
 This Note is one of the Citiseries, Class 2017-A8 Notes issued pursuant to the Second Amended and Restated
Indenture dated as of September 26, 2000, as amended and restated as of August 9, 2011, and as further amended and restated as of November 10, 2016 (as so further amended and restated and otherwise modified from time to time, the
“Indenture”), between the Issuer and Deutsche Bank Trust Company Americas, as Trustee. For purposes of this Note, the term “Indenture” includes any supplemental indenture or Issuer Certificate relating to the Citiseries, Class
2017-A8 Notes. This Note is subject to all of the terms of the Indenture. All terms used in this Note that are not otherwise defined herein and that are defined in the Indenture will have the meanings assigned to them therein. 

The principal of and interest on this Note are payable in such coin or currency of the United States of America as at the time of payment is legal tender for
payment of public and private debts. 
 Reference is made to the further provisions of this Note set forth on the reverse hereof, which will have the same
effect as though fully set forth on the face of this Note. 
 Unless the certificate of authentication hereon has been executed by the Trustee whose name
appears below by manual signature, this Note will not be entitled to any benefit under the Indenture, or be valid or obligatory for any purpose. 

  

 IN WITNESS WHEREOF, the Issuer has caused this instrument to be signed, manually or in facsimile, by an Issuer
Authorized Officer. 
  

					
	 CITIBANK CREDIT CARD ISSUANCE TRUST

		
	By:	 	    CITIBANK, N.A.,
    as Managing Beneficiary of
    Citibank Credit Card Issuance Trust
			
		 	By:	 	  

		 		 	[Name]
		 		 	[Title]

 Dated: August 8, 2017 

TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

This is one of the Notes designated above and referred to in the within mentioned Indenture. 

 

			
	 DEUTSCHE BANK TRUST COMPANY AMERICAS,

as Trustee under the Indenture

 
			
		
	By:	 	  

		 	Authorized Signatory
		 	

 Dated: August 8, 2017 

  

 REVERSE OF NOTE 

This Note is one of a duly authorized issue of Notes of the Issuer, designated as its Citiseries 1.86% Class 2017-A8 Notes of August 2020 (Legal Maturity Date
August 2022) (herein called the “Notes”), all issued under an Indenture, to which Indenture reference is hereby made for a statement of the respective rights and obligations thereunder of the Issuer, the Trustee and the Holders of the
Notes. 
 This Note ranks pari passu with all other Class A Notes of the same series, as set forth in the Indenture. This Note is secured to the
extent, and by the collateral, described in the Indenture. 
 The Issuer will pay interest on overdue interest as set forth in the Indenture to the extent
lawful. 
 Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a beneficial interest in this Note,
agrees that no recourse may be taken, directly or indirectly, with respect to the obligations of the Issuer or the Trustee on the Notes, against the Issuer, the Issuer Trustee, Citibank, N.A., the Trustee or any affiliate, officer, employee or
director of any of them, and the obligation of the Issuer to pay principal of or interest on this Note or any other amount payable to the Holder of this Note will be subject to Article V of the Indenture. 

Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a beneficial interest in this Note, in each case
other than Citibank, N.A. as Holder or owner, agrees that this Note is intended to be debt of Citibank, N.A. for federal, state and local income and franchise tax purposes, and agrees to treat this Note accordingly for all such purposes, unless
otherwise required by a taxing authority. 
 Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a
beneficial interest in this Note, agrees that it will not at any time institute against the Issuer, or join in any institution against the Issuer of, any bankruptcy, reorganization, arrangement, insolvency or liquidation proceeding, or other
proceedings under any United States federal or state bankruptcy or similar law in connection with any obligations relating to this Note, the Indenture or any Derivative Agreement. 

This Note and the Indenture will be construed in accordance with and governed by the laws of the State of New York. 

Certain amendments may be made to the Indenture without the consent of the Holder of this Note. This Note must be surrendered for final payment of principal
and interest. 

  

 ASSIGNMENT 

Social Security or taxpayer I.D. or other identifying number of
assignee:                                       
          
 FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto 

 

	
	  

	
	  

	(name and address of assignee)

 the within Note and all rights thereunder, and hereby irrevocably constitutes and appoints
                                         
                                         
                      , attorney, to transfer said Note on the books kept for registration thereof, with full power of substitution in
the premises. 
  

			
	Dated:
                                         
                   	 	                                      
                                         
         *
		 	Signature Guaranteed:

  

	*	NOTE: The signature to this assignment must correspond with the name of the registered owner as it appears on the face of the within Note in every particular without alteration, enlargement or any change whatsoever.Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This
EMPLOYMENT AGREEMENT (the “Agreement”) is dated and entered into as of July 28, 2017 by and between
PhotoMedex, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and Stephen
Johnson (the “Executive”).

 

WHEREAS,
the Company desires to employ the Executive, and the Executive desires to be employed by the Company, in each case on the terms
and conditions contained herein.

 

NOW,
THEREFORE, in consideration of the foregoing premises and mutual covenants and agreements herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

 

1.       Term
of Employment. Subject to the provisions of Section 5 of this Agreement, the Executive shall be employed by the Company for
a period commencing on May 17, 2017 (the “Effective Date”) and ending on the second (2nd) anniversary
of the Effective Date (the “Term”). The Term shall be renewed automatically for additional one (1) year period(s)
unless terminated by either the Company or the Executive in writing by notice to Executive delivered no fewer than ninety (90)
days prior to expiration of the then-applicable Term.

 

2.       Position.

 

(a)       Duties.
The principal duty of the Executive shall be to serve in the position of Chief Financial Officer of the Company. In such capacity,
the Executive shall be responsible for the finances of the Company, subject to the direction and control of the Board of Directors
of the Company (the “Board”). All references to the “Board” in this Agreement shall include any
committee of the Board (including the Compensation Committee of the Board) that has been or is in the future delegated the power
of the Board to oversee and manage the compensation of the Company’s officers and employees.

 

(b)       Devotion
of Time to Company’s Business. The Executive shall use his best efforts, skills and abilities to promote and
protect the interests of the Company and devote sufficient working time and energies to the business and affairs of the
Company. The Company acknowledges and agrees that the Executive has and will continue to have executive and management
responsibilities to First Capital Real Estate Trust Incorporated and its subsidiaries and affiliates (collectively,
“First Capital”) and that nothing in this Agreement shall be construed to restrict or otherwise affect the
obligations of the Executive to First Capital. Further, notwithstanding anything to the contrary contained herein, the
Executive (i) may serve on the board(s) of additional companies or organizations and receive compensation for such services
rendered (ii) may engage in charitable, civic, fraternal, professional, trade association or other activities on behalf of
private companies and receive compensation for such services rendered, provided that in each such case the activities engaged
in by the Executive do not materially interfere with his obligations to the Company, and do not compete with the Company.

 

(c)       Directors and
Officers Liability Insurance. During the Term and for a period of six years thereafter, the Company, or any successor to the
Company resulting from a change in control, shall maintain a directors and officers liability insurance policy (or policies) in
a minimum amount of $5,000,000 which shall provide comprehensive coverage to Executive.

 

(d)       Best
Efforts. The Executive shall use his best efforts to carry out and successfully complete the assignments, tasks and job
activities required, from time to time, to be performed to carry out Executive’s duties and responsibilities during the
Term. The Executive’s duties and assignments shall be undertaken at such location(s) as may be determined from time to
time by the Company, but in no event shall Executive be required to perform his duties on a regular basis at any location
more than 25 miles from the location where Executive regularly performs his duties for the Company immediately prior to the
Effective Date.

 

     1

     

    

 

(e)       Company Rules,
Policies and Regulations. The Executive shall, at all times, conduct himself in a professional manner and adhere to the standards,
ethical obligations, rules, policies, regulations and procedures of the Company which are presently in force or which may be established
from time to time by the Company. Executive shall take no intentional action that violates any law, rule or regulation whatsoever
while acting in his capacity as employee.

 

3.       Compensation
and Benefits.

 

(a)       Base Salary.
As of the Effective Date, the Executive shall be paid a base salary in consideration for his services provided to the Company at
the rate of $300,000 per annum (the “Base Salary”), payable in accordance with the Company’s normal payroll
practices. Increases in Base Salary during the Term shall be determined from time to time in the sole discretion of the Board based
upon such criteria as they deem relevant, or based on no particular criteria whatsoever.

 

(b)       Additional
Compensation. The Executive shall be entitled to a bonus of not less than 35% of his Base Salary subject to achieving
milestones that will be set by the Company’s compensation committee within thirty (30) days after the compensation
committee receives a business plan for the Company from the Executive and the Chief Executive Officer of the Company. The
Executive shall also be entitled to equity compensation in an amount and with a vesting schedule to be determined in good
faith by the Company’s compensation committee within thirty (30) days after the compensation committee receives a
business plan for the Company from the Executive and the Chief Executive Officer of the Company. This Agreement shall be
promptly amended to reflect such compensation.

 

(c)       Withholding.
All salaries, bonuses and other benefits payable to the Executive shall be subject to payroll, withholding and other taxes or deductions
as may be required by law.

 

4.       Employee Benefits;
Business Expenses.

 

(a)       Employee
Benefits. During the Term, the Executive and his dependents shall be entitled to participate in the Company’s
healthcare plans, welfare benefit plans, life insurance plans or policies, fringe benefit plans and any qualified or
non-qualified retirement plans as in effect from time to time (collectively, the “Employee Benefits”), on
the same basis as those benefits are made available to the other senior executives of the Company, in accordance with the
Company policy as in effect from time to time and in accordance with the terms of the applicable plan documents (if any). If
at any time the Company does provide a health insurance plan for which the Executive is eligible, the Executive shall be
entitled to reimbursement by the Company of the cost of health insurance paid by the Executive for the Executive and his
family. Any such reimbursement shall be paid to the Executive not later than March 15 of the year following the calendar year
in which the Executive paid such cost. To the extent that the Company does not provide a health insurance plan for which the
Executive is eligible, the Executive shall be entitled to reimbursement by the Company of the cost of health insurance paid
by the Executive for the Executive and his family, which reimbursement shall be grossed-up to cover any taxes the Executive
would be required to pay as the result of the Company reimbursing the Executive for the cost of the Executive’s health
plan.

 

(b)       Perquisites.
During the Term, the Executive shall be entitled to receive such perquisites as are or have previously been made available to other
senior executives of the Company in accordance with Company policies as in effect from time to time.

 

     2

     

    

 

(c)       Expenses.
The Executive shall be entitled to reimbursement for reasonable and necessary business expenses incurred by him in the performance
of his duties and responsibilities hereunder, such expenses to be documented and reimbursed in accordance with the Company’s
reimbursement and expenses policies as in effect from time to time.

 

(d)       Vacation.
The Executive shall be entitled to four (4) weeks paid vacation per annum; provided, that the Executive shall be paid annually
in cash for vacation days not taken by him; provided that no more than four (4) weeks of vacation may be accrued each year for
purposes of such cash payments; and provided further that any such payment shall be paid to the Executive not later than March
15 of the year following the calendar year in which the unused vacation days accrued.

 

5.       Termination.

 

  (a)       Definitions.
For purposes of this Agreement:

 

  (i)        “Cause” shall mean (A) the Executive’s
gross negligence and/or willful misconduct (as such terms are generally understood and applied to the performance of an executive)
in the performance of his material duties with respect to the Company as determined, in each case, by a court of competent jurisdiction
not subject to further appeal or a final arbitration award, as provided hereunder, (B) the conviction by the Executive of a crime
constituting a felony or (C) the Executive shall have committed any material act of malfeasance, disloyalty, dishonesty or breach
of fiduciary duty against the Company, for which the Executive shall have a ten (10) day cure period following notice thereof from
the Company (except for a conviction pursuant to subsection (B), for which there shall be no cure period).

 

  (ii)       “Change of Control” means the occurrence
of any one or more of the following events (it being agreed that, with respect to paragraphs (A) and (C) of this definition below,
a “Change of Control” shall not be deemed to have occurred if the applicable third party acquiring party is an “affiliate”
of the Company within the meaning of Rule 405 promulgated under the Securities Act of 1933, as amended):

 

		(A)	An acquisition (whether directly from the Company or
otherwise) of any voting securities of the Company (the “Voting Securities”) by any “Person”
(as the term person is used for purposes of Section 13(d) or 14(d) of the Securities and Exchange Act of 1934, as amended (the
“1934 Act”)), immediately after which such Person has “Beneficial Ownership” (within the meaning
of Rule 13d-3 promulgated under the 1934 Act) of forty percent (40%) or more of the combined voting power of the Company’s
then outstanding Voting Securities; or

 

(B)        The individuals
who, as of the consummation of any transaction or series of related transactions described in paragraphs (A) and (C) of this definition,
are members of the Board cease, by reason of transactions, to constitute at least fifty-one percent (51%) of the members of the
Board; or

 

(C)        The consummation, in one or a series of related transactions, of:

 

(I)          A merger, consolidation or reorganization
involving the Company, where either or both of the events described in clauses (A) or (B) above would be the result; or

 

     3

     

    

 

(II)          The sale or other disposition of all or substantially
all of the assets of the Company to any Person (other than a transfer to a subsidiary of the Company).

 

  (iii)      “Date of Termination” shall mean
the date the Notice of Termination is given to the respective party; provided, however, that with respect to a termination for
Cause by the Company, the Date of Termination shall not occur prior to the expiration of any applicable cure period.

 

  (iv)     “Disability” shall mean the
Executive has become physically or mentally incapacitated and is therefore unable for a period of four (4) consecutive months
to perform any of the material elements of his duties hereunder. Any question as to whether the Executive has a Disability as
to which he (or his legal representative) and the Company cannot agree shall be determined in writing by a qualified
independent physician mutually acceptable to the Executive (or his legal representative) and the Company. If the Executive
(or his legal representative) and the Company cannot agree as to a qualified independent physician, each shall appoint such a
physician and those two physicians shall select a third who shall make such determination in writing. The determination of
whether the Executive has a Disability, as made in writing to the Company and the Executive by such physician(s), shall be
final and conclusive for all purposes of this Agreement.

 

  (v)       “Good
Reason” shall mean (A) a breach by the Company of any of its material obligations or covenants or change to any of
the material terms set forth in this Agreement, (B) a material reduction of the duties, responsibilities or title of the
Executive, (C) the assignment to the Executive of any duties or responsibilities that are inconsistent, in any significant
respect, with his position, for which the Company shall have a ten (10) day cure period following notice thereof from
Executive to the Company, (D) an abandonment of, or fundamental change in, the primary business or primary products of the
Company, (E) a Change of Control, but only if the Executive’s termination occurs within twelve (12) months after the
occurrence of such Change of Control.

 

  (vi)      “Notice of Termination” shall mean
a notice which shall indicate the specific termination provision in this Agreement relied upon and shall set forth in reasonable
detail the facts and circumstances claimed to provide a basis for termination of employment under the provision so indicated, and
shall be communicated, in writing, to the other party hereto in accordance with the provisions of Section 6(g) hereof.

 

  (b)      By the Company
for Cause or by the Executive Without Good Reason.

 

  (i)        The Term and the Executive’s employment hereunder
may be terminated by the Company for Cause, immediately upon the delivery of a Notice of Termination by the Company to the Executive
(except where the Executive is entitled to a cure period hereunder, in which case such Date of Termination shall be upon the expiration
of such cure period if such matter constituting Cause is not cured) and shall terminate automatically upon the Executive’s
resignation (other than for Good Reason or due to the Executive’s death or Disability).

 

     4

     

    

 

  (ii)       If the Executive’s employment is terminated
by the Company for Cause, or if the Executive resigns other than for Good Reason, the Executive shall be entitled to
receive:

 

(A)       any earned but
unpaid Base Salary and/or accrued but unused vacation, all vested equity, and any earned but unpaid bonus awards through the Date
of Termination,

 

(B)        reimbursement for
any unreimbursed business expenses incurred by the Executive in accordance with the Company’s policy prior to the Date of
Termination (with such reimbursements to be paid promptly after the Executive provides the Company with the necessary documentation
of such expenses to the extent required by such policy but in no event later than the end of the second calendar month following
the year in which the Date of Termination occurred), and

 

(C)        such Employee Benefits,
if any, as to which he may be entitled upon termination of employment under the terms of the plan documents and applicable law
(including under the applicable provisions of Consolidated Omnibus Budget Reconciliation Act of 1985, as amended).

 

Following the Executive’s termination of employment
by the Company for Cause or if he resigns other than for Good Reason, except as set forth above or as required by applicable
law, the Executive shall have no further rights to any compensation or any other benefits or perquisites under this Agreement
and all unvested option or restricted stock grant awards shall immediately be cancelled without the need for any action by
the Company.

 

  (c)       By the Company
Other Than for Cause or by the Executive for Good Reason.

 

  (i)        The Term and the Executive’s employment hereunder
may be terminated by the Company other than for Cause, immediately upon the delivery of a Notice of Termination by the Company
to the Executive and shall terminate automatically and immediately upon the Executive’s resignation for Good Reason at the
end of any applicable cure period if the circumstances giving rise to Good Reason are not cured.

 

  (ii)       If the Executive’s employment is terminated by
the Company other than for Cause, or if the Executive resigns for Good Reason, the Executive shall receive and the Company shall
pay to Executive on the Date of Termination:

 

(A)       any earned but
unpaid Base Salary and/or accrued but unused vacation, all vested equity, and any earned but unpaid bonus awards through the Date
of Termination, plus an additional twelve (12) months of Annual Compensation (other than the case of a Change of Control, in which
case the payment shall be an additional eighteen (18) months of Annual Compensation), together in a lump sum payment;

 

(B)        acceleration of
any then-unvested stock options, restricted stock grants or other equity awards;

 

(C)        payment or
reimbursement, as applicable, of the full health insurance costs for the Executive and his family under a Company-provided
group health plan or otherwise for twenty-four (24) months following termination by the Company other than for Cause or
resignation by Executive for Good Reason, provided that any such payment or reimbursement which constitutes deferred
compensation under Section 409A (“Section 409A”) of the Internal Revenue Code of 1986, as amended
(“Code”), shall be made annually within thirty (30) days after the end of the calendar year in which the
health insurance costs were incurred;

 

     5

     

    

 

(D)       in the event any
bonus or other form of additional compensation is paid to any other executive(s) of the Company for the fiscal year during which
Executive’s employment ceased pursuant to this Section 5(c), a cash amount equal to the largest bonus or other form of additional
compensation payment made by the Company to any other executive of the Company during such fiscal year, provided that in the event
such bonus or other form of compensation is not ascertainable on the Date of Termination, such payment shall be made no later than
March 15 of the year following the calendar year in which the Date of Termination occurred;

 

(E)        reimbursement for
any accrued but unused vacation days and/or unreimbursed business expenses incurred by the Executive in accordance with the Company’s
policy prior to the Date of Termination (with such reimbursements to be paid promptly after the Executive provides the Company
with the necessary documentation of such expenses to the extent required by such policy but in no event later than the end of the
second calendar month following the year in which the Date of Termination occurred); and

 

(F)        such other Employee
Benefits, if any, as to which he may be entitled upon termination of employment hereunder.

 

Following the Executive’s termination of employment
by the Company other than for Cause or if he resigns for Good Reason, except as set forth above or as required by applicable
law, the Executive shall have no further rights to any compensation or any other benefits under this Agreement.
Notwithstanding the foregoing, in order to be eligible for any of the severance payments and benefits under this Section
5(c), the Executive must execute and deliver to the Company a general release in a form reasonably satisfactory to the Board.
If the payments to be made under this Section 5(c) are otherwise subject to Section 409A, they shall be made, or commence to
be made, on the first pay period following the date that is thirty (30) days after the Executive’s employment
terminates. If the payments are not otherwise subject to Section 409A, they shall be made, or commence to be made, on the
first business day after the release becomes effective. The initial payment shall include any unpaid amounts from the date
the Executive’s employment terminated, subject to the Executive’s executing and delivering the release on the
terms as set forth above.

 

  (d)       Death or
Disability. The Executive’s employment hereunder shall terminate upon the Executive’s death and may be
terminated by the Company, within ten (10) days after the delivery of a Notice of Termination by the Company to the Executive
(or his legal representative) in the event of the Executive’s Disability. Upon termination of the Executive’s
employment hereunder for either Disability or death, the Executive shall be entitled to receive the same payments and other
items as set forth in clause (ii) of Section 5(b) hereof, except that Executive (in case of Disability) or the estate (in the
event of death) shall have the right to exercise any unexercised and vested options for a period of 90 days, and, in
addition, to receive payment for accrued but unpaid vacation time, if any. Following the Executive’s termination of
employment due to death or Disability, except as set forth herein or as required by applicable law, the Executive (nor his
estate) shall have no further rights to any compensation or any other benefits under this Agreement.

 

  (e)       Payment of
Amounts Owed upon Termination of Employment. Unless otherwise provided herein, any amounts payable to the Executive for earned
but unpaid Base Salary and cash, equity or other bonus awards through the Date of Termination shall be paid within ten (10) business
days after the Date of Termination.

 

     6

     

    

 

6.       Miscellaneous.

 

  (a)       Governing Law.
This Agreement shall be construed and governed under and by the laws of the State of New York, without regard to the conflicts
of laws principles thereof.

 

  (b)       Arbitration
of Claims. In the event of any dispute, claim, question or disagreement arising from or relating to this Agreement or the
breach thereof (and except for cases in which the Company is entitled to injunctive or other equitable relief as described in
Section 9 hereof), the Company and Executive agree to settle the dispute, claim, question or disagreement by arbitration before
a single arbitrator in the City of New York, New York, selected by, and such arbitration to be administered by, the American Arbitration
Association (“AAA”) in accordance with its Commercial Arbitration Rules, and judgment on the award rendered
by the arbitrator may be entered in any court having jurisdiction thereof. Each of the Company and Executive hereby agrees and
acknowledges that all disputes between or among them are subject to the alternative dispute resolution procedures of this Section
6(b). Each of the Company and Executive agrees that any aspect of alternative dispute resolution not specifically covered in this
Agreement shall be covered, without limitation, by the applicable AAA rules and procedures. Each of the Company and Executive
further agree that any determination by the arbitrator regarding any dispute, claim, question or disagreement arising from or
relating to this Agreement shall be final and binding upon the parties hereto and shall not be subject to further appeal. Each
of the Company and Executive shall bear its own costs and expenses and an equal share of the arbitrator’s fees and administrative
fees of arbitration; provided, however, that upon receipt of the determination by the arbitrator the prevailing party shall have
all reasonable out-of-pocket fees and expenses reimbursed promptly (in all events within 10 calendar days following delivery to
both parties of the arbitrator’s decision) by the non-prevailing party in any such dispute.

 

  (c)       Entire Agreement;
Amendments. This Agreement sets forth the entire understanding of the parties concerning the subject matter of this Agreement
and incorporates all prior negotiations and understandings. There are no covenants, promises, agreements, conditions or understandings,
either oral or written, between them relating to the subject matter of this Agreement other than those set forth herein. The publication,
amendment, supplementation or replacement of an employee handbook by the Company shall not be deemed to alter, amend or modify
the terms and conditions of this Agreement. No alteration, amendment, change or addition to this Agreement shall be binding upon
any party unless in writing and signed by the party to be charged. No purported waiver by any party of any default by another party
of any term or provision contained herein shall be deemed to be a waiver of such term or provision unless the waiver is in writing
and signed by the waiving party. No such waiver shall in any event be deemed a waiver of any subsequent default under the same
or any other term or provision contained herein. This Agreement may not be altered, modified, or amended except by written instrument
signed by the parties hereto.

 

  (d)       No Waiver.
No waiver of any of the provisions of this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed
or be construed as a further, continuing or subsequent waiver of any such provision or as a waiver of any other provision of this
Agreement. No failure to exercise and no delay in exercising any right, remedy or power hereunder will preclude any other or further
exercise of any other right, remedy or power provided herein or by law or in equity.

 

  (e)       Severability.
If any term or provisions of this Agreement, or the application thereof to any person or circumstance, shall be invalid or unenforceable,
the remainder of this Agreement, or the application of such term or provision to persons or circumstances, other than those as
to which it is held invalid, shall both be unaffected thereby and each term or provision of this Agreement shall be valid and be
enforced to the fullest extent permitted by law.

 

     7

     

    

 

  (f)        Assignment. This Agreement, and the Executive’s
rights and duties hereunder, shall not be assignable or delegable by the Executive; provided, however, that if the Executive shall
die, all amounts then payable to the Executive hereunder shall be paid in accordance with the terms of this Agreement to the Executive’s
devisee, legatee or other designee or, if there be no such devisee, legatee or designee, to his estate. Upon such assignment, the
rights and obligations of the Company hereunder shall become the rights and obligations of such affiliate or successor person or
entity.

 

  (g)       Notices.
For the purpose of this Agreement, notices and all other communications provided for in the Agreement shall be in writing and shall
be deemed to have been duly given when delivered by hand or internationally recognized courier service addressed to the respective
addresses set forth below in this Agreement, or via facsimile or email transmission to the number or email address set forth below,
or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice
of change of address shall be effective only upon receipt.

 

  If to the Company:

 

Board of Directors

PhotoMedex, Inc.

2300 Computer Drive, Building
G

Willow Grove, PA 19090

Attention: Suneet
Singal

 

  If
to the Executive:

 

Stephen Johnson

_______________

_______________

 

  (h)      Prior Agreements. This Agreement supersedes all
prior agreements and understandings (including verbal agreements) between the Executive and the Company regarding the terms and
conditions of the Executive’s employment with the Company.

 

  (i)       Cooperation. The Executive shall provide his reasonable
cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring
during the Executive’s employment hereunder, but only to the extent the Company requests such cooperation with reasonable
advance notice to the Executive and in respect of such periods of time as shall not unreasonably interfere with the Executive’s
ability to perform his duties with any subsequent employer; provided, however, the Company shall pay any reasonable travel, lodging
and related expenses that the Executive may incur in connection with providing all such cooperation, to the extent approved by
the Company prior to incurring such expenses.

 

  (j)       Execution and
Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof.

 

     8

     

    

 

  (k)       Section 409A.

 

  (i)        The parties intend that the payments and benefits
provided for in this Agreement either be exempt from Section 409A, or be provided in a manner that complies with Section 409A
and any ambiguity herein shall be interpreted so as to be consistent with the intent of this paragraph. In no event
whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on the Executive by
Section 409A or damages for failing to comply with Section 409A. Notwithstanding anything contained herein to the contrary,
all payments and benefits which are payable upon a termination of employment hereunder shall be paid or provided only upon
those terminations of employment that constitute a “separation from service” from the Company within the meaning
of Section 409A (determined after applying the presumptions set forth in Treas. Reg. Section 1.409A-1(h)(1)). Further, if the
Executive is a “specified employee” as such term is defined under Section 409A at the time of a termination of
employment and the deferral of the commencement of any payments or benefits otherwise payable hereunder as a result of such
termination of employment is necessary in order to prevent any accelerated recognition of income or additional tax under
Section 409A, then the Company will defer the commencement of the payment of any such payments or benefits hereunder (without
any reduction in payments or benefits ultimately paid or provided to the Executive) until the date that is at least six (6)
months following the Executive’s termination of employment with the Company (or the earliest date permitted under
Section 409A, e.g., immediately upon the Executive’s death), whereupon the Company will promptly pay the Executive a
lump-sum amount equal to the cumulative amounts that would have otherwise been previously paid to the Executive under this
Agreement during the period in which such payments or benefits were deferred. Thereafter, payments will resume in accordance
with this Agreement.

 

  (ii)       Notwithstanding anything to the contrary in this Agreement,
in-kind benefits and reimbursements provided hereunder during any calendar year shall not affect in-kind benefits or reimbursements
to be provided in any other calendar year, other than an arrangement providing for the reimbursement of medical expenses referred
to in Section 105(b) of the Code, and are not subject to liquidation or exchange for another benefit. Notwithstanding anything
to the contrary in this Agreement, reimbursement requests must be timely submitted by the Executive and, if timely submitted, reimbursement
payments shall be promptly made to the Executive following such submission, but in no event later than December 31st of the calendar
year following the calendar year in which the expense was incurred. In no event shall the Executive be entitled to any reimbursement
payments after December 31st of the calendar year following the calendar year in which the expense was incurred. This paragraph
shall only apply to in-kind benefits and reimbursements that would result in taxable compensation income to the Executive.

 

  (iii)      Additionally, in the event that following the
date hereof the Company or the Executive reasonably determines that any compensation or benefits payable under this Agreement
may be subject to Section 409A, the Company and the Executive shall work together to adopt such amendments to this Agreement
or adopt other policies or procedures (including amendments, policies and procedures with retroactive effect), or take any
other commercially reasonable actions necessary or appropriate to (x) exempt the compensation and benefits payable under this
Agreement from Section 409A and/or preserve the intended tax treatment of the compensation and benefits provided with respect
to this Agreement or (y) comply with the requirements of Section 409A.

 

[Signature Page Follows]

 

     9

     

    

 

IN WITNESS WHEREOF, the parties hereto have duly executed
this Agreement as of the day and year first above written.

	 	 	 	 
	 	PHOTOMEDEX, INC.	 
	 	 	 
	 	By:	/s/ Dr. Bob Froehlich	 
	 		Name:
Dr. Bob Froehlich	 
	 	 	Title: Chairman	 
	 	 	 	 
	 	EXECUTIVE:	 
	 	 	 	 
	 	/s/ Stephen Johnson	 
	 	Stephen
Johnson	 

 

[Signature Page to Employment Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]